Albert Robichaud currently serves as a Partner at Cure Ventures Capital, a position held since January 2024. Prior to this, Robichaud worked as a Scientist at 73 R&D Consulting, providing expertise in Pharma Research and Development with a focus on Neuroscience. From November 2011 to September 2023, Robichaud was the Chief Scientific Officer at Sage Therapeutics, a company dedicated to developing therapies for central nervous system disorders. Robichaud also held the role of Vice President at Lundbeck Research in the USA from January 2010 to November 2011, overseeing the Chemical & Pharmacokinetic Sciences group. Earlier experience includes serving as Senior Director and Head of the Princeton Chemistry Department at Wyeth Pharmaceuticals from June 2002 to January 2010. Academic qualifications include a PhD in Organic Chemistry from UC Irvine and postdoctoral training at Colorado State University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices